|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
3i joins as new investor in Sweden's Carmel Pharma
December 20th, 2005 No comments
SLS Venture has signed an agreement to sell about 23 % of Carmel Pharma to 3i, Europe’s leading venture capital and private equity company. 3i will also participate in the company’s present issue of new shares.
Carmel Pharma is a company in Sweden that manufactures and markets PhaSeal, a product system for the handling of toxic drugs, and minimizing the spread of aerosols into the work environment. Carmel Pharma is one of the fastest growing technology companies in Europe, the Middle East and Africa.
Most Swedish national hospitals treating cancer patients use PhaSeal products. Carmel Pharma primary market today is the USA, and has expanded its operations to the US in recent years. Hundreds of American hospitals use the product on a routine basis and the company’s sales volumes have grown nearly 40% in the past year alone, and are expected to grow more in 2006.
Thomas Pollare, Partner, Venture Team, 3i Nordic says: “Carmel Pharma is an exciting company in expansion phase. PhaSeal has great development opportunities and we strongly believe in Managing Director Dan Pitulia and his management team’s ability to successfully take the company to the next stage. Based on 3i’s long medtech investing experience and international network contacts and resource, we look forward to actively helping Carmel Pharma with its international expansion.”
Dan Pitulia, Managing Director, Carmel Pharma, comments: “It is great to have 3i backing our company. In 3i we will have a new financially strong partner with an international network and long experience on business development. Our objective is to further strengthen our world leading position through strong organic growth.”
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility